Ticagrelor

Ticagrelor
	File:Ticagrelor structure.svg
Clinical data
Routes of; administration	oral
ATC code	none;
Identifiers
	IUPAC name (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;
CAS Number	274693-27-5;
PubChem CID	9871419;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H28F2N6O4S
Molar mass	522.567 g/mol
3D model (JSmol)	Interactive image;
	SMILES Fc2ccc(cc2F)C3CC3Nc5nc(SCCC)nc4c5nnn4C1CC(C(O)C1O)OCCO;

Ticagrelor (AZD6140) is a platelet aggregation inhibitor produced by AstraZeneca. As of February 2008^[update], a clinical trial (PLATO: Platelet inhibition and patient outcomes) is comparing a combination of ticagrelor plus aspirin to clopidogrel plus aspirin for the prevention of thromboembolism.

Method of action

Like clopidogrel and ticlopidine, ticagrelor blocks ADP receptors of subtype P2Y₁₂. In contrast to the other antiplatelet drugs, the blockage is reversible. Moreover, it does not need hepatic activation, which could reduce the risk of drug interactions.^[1]^[2]

PLATO trial

This trial, recently published in New England Journal of Medicine, has confirmed the superiority of ticagrelor over clopidogel in patients with acute coronary syndromes.^[3]

References

↑ H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135. Check date values in: |date= (help)
↑ Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.
↑ Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.

Template:Pharma-stub

[1] H. Spreitzer (February 4, 2008). "Neue Wirkstoffe - AZD6140". Österreichische Apothekerzeitung (in German) (3/2008): 135. Check date values in: |date= (help)

[2] Owen, RT, Serradell, N, Bolos, J (2007). "AZD6140". Drugs of the Future. 32 (10): 845–853. doi:10.1358/dof.2007.032.10.1133832.

[3] Wallentin, Lars (August 30, 2009). "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". NEJM.

[1]

[2]

[3]

Clinical data
File:Ticagrelor structure.svg
Routes of administration	oral
ATC code	none
Identifiers
IUPAC name (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
CAS Number	274693-27-5
PubChem CID	9871419
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₂₈F₂N₆O₄S
Molar mass	522.567 g/mol
3D model (JSmol)	Interactive image
SMILES Fc2ccc(cc2F)C3CC3Nc5nc(SCCC)nc4c5nnn4C1CC(C(O)C1O)OCCO

Ticagrelor

Method of action

PLATO trial

References

Navigation menu